Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321925 · ClinicalTrials.gov registry record
Thermoacoustic Method for Estimating Liver Fat Fraction
A clinical trial of Fatty Liver Disease, Nonalcoholic and MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), sponsored by Endra Lifesciences.
- Recruiting
- Registry status
- 49
- Enrollment target
- 1
- Study location
NCT07321925: Recruiting study of Fatty Liver Disease, Nonalcoholic and MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), sponsored by Endra Lifesciences.
NCT07321925 is a study of Fatty Liver Disease, Nonalcoholic and MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) that is actively recruiting participants, run by Endra Lifesciences. The registered enrollment target is 49 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07321925, a study of Fatty Liver Disease, Nonalcoholic and MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), is actively recruiting participants, sponsored by Endra Lifesciences.
- RECRUITING
- Registry status
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements. Participants will have a scan with our device, then they will go have an abdominal MRI completed. The goal is to create a more accessible device to measure liver fat as it is an indicator for overall health and metabolic diseases.
Primary Outcome
The correlation between TAFF and the MRI-PDFF, will be conducted using the calculation of the cumulative distribution of the correlation coefficient as derived by Guenther
Conditions Studied
Interventions
- DEVICE Thermoacoustic Enhanced Ultrasound
Study Locations (1)
Michigan
- ENDRA Life Sciences - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2025-12-31 |
What NCT07321925 shows while recruiting
NCT07321925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 2 conditions, with Fatty Liver Disease, Nonalcoholic appearing as the primary indexed condition, and to 1 intervention - of which Thermoacoustic Enhanced Ultrasound is the first listed.
NCT07321925 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07321925 about?
NCT07321925 is a clinical study titled "Thermoacoustic Method for Estimating Liver Fat Fraction". The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements. Participants will have a scan with our device, then they will go have an abdominal MRI completed. The goal is to creat...
What is the current status of trial NCT07321925?
This trial is currently recruiting. The enrollment target is 49 participants. The study started on 2025-08-15. Estimated completion is 2025-12-31.
What conditions does trial NCT07321925 study?
This clinical trial studies the following conditions: Fatty Liver Disease, Nonalcoholic, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis).
What interventions are being tested in trial NCT07321925?
The interventions under investigation include: Thermoacoustic Enhanced Ultrasound (DEVICE).
Who is sponsoring clinical trial NCT07321925?
This trial is sponsored by Endra Lifesciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321925 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatty Liver Disease, Nonalcoholic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI